(Q37035241)

17 August 2017

1 reference

title

Neurobiology of bipolar disorder (English)

1 reference

17 August 2017

1 reference

Andrew R Newberg

1

1 reference

17 August 2017

Lisa A Catapano

series ordinal

2

1 reference

17 August 2017

Carlos A Zarate

series ordinal

3

1 reference

17 August 2017

Husseini K Manji

series ordinal

4

1 reference

17 August 2017

publication date

1 January 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

1

1 reference

17 August 2017

page(s)

93-110

1 reference

A cholinergic-adrenergic hypothesis of mania and depression

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Functional impairment in the remission phase of bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Bipolar disorder and health-related quality of life : review of burden of disease and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

G protein-coupled receptors in major psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Mechanisms of action of valproate: a commentatory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Stress and hippocampal plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Lithium acutely inhibits and chronically up-regulates and stabilizes glutamate uptake by presynaptic nerve endings in mouse cerebral cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Neuroprotective effects of chronic lithium on focal cerebral ischemia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Inhibition of [3H]alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid [AMPA] binding by the anticonvulsant valproate in clinically relevant concentrations: an autoradiographic investigation in human hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Structurally dissimilar antimanic agents modulate synaptic plasticity by regulating AMPA glutamate receptor subunit GluR1 synaptic expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Up-regulation of hippocampal glutamate transport during chronic treatment with sodium valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

The prognostic significance of thyroid function in mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Hyperthyroxinemia in major affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Psychoneuroendocrinology of mood disorders. The hypothalamic-pituitary-thyroid axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Potentiation of antidepressant effects by L-triiodothyronine in tricyclic nonresponders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Thyroid-induced mania in hypothyroid patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Thyrotrophin releasing hormone: endocrine and central effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Stress and the aging hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

The neurobiology of stress: from serendipity to clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Melancholia: restoration in psychiatric classification recommended

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Electroconvulsive therapy in melancholia: the role of hippocampal neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Regional specificity of brain glucocorticoid receptor mRNA alterations in subjects with schizophrenia and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Mineralocorticoid receptor function in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Limited efficacy of ketoconazole in treatment-refractory major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Antiglucocorticoid treatment of depression: double-blind ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Rapid reversal of psychotic depression using mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Dehydroepiandrosterone treatment of midlife dysthymia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

No abnormality in the gene for the G protein stimulatory alpha subunit in patients with bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

A bimodal model of the mechanism of action of lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D(2)-like receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Reduced Brain Inositol in Lithium-treated Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Specificity of mood stabilizer action on neuronal growth cones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

The high affinity inositol transport system--implications for the pathophysiology and treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Sodium-myo-inositol co-transporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Chronic lithium administration alters a prominent PKC substrate in rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

A pilot study of hormone modulation as a new treatment for mania in women with bipolar affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: molecular transduction of mood stabilization in the treatment of manic-depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Volumetric brain imaging findings in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Glial reduction in the subgenual prefrontal cortex in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Electron microscopy of oligodendroglia in severe mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Oligodendrocyte dysfunction in schizophrenia and bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Mitochondrial dysfunction in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

The other, forgotten genome: mitochondrial DNA and mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Mechanisms of altered Ca2+ signalling in transformed lymphoblastoid cells from patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Molecular evidence for mitochondrial dysfunction in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

The anti-apoptotic, glucocorticoid receptor cochaperone protein BAG-1 is a long-term target for the actions of mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Support of retinal ganglion cell survival and axon regeneration by lithium through a Bcl-2-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Increased generation of granule cells in adult Bcl-2-overexpressing mice: a role for cell death during continued hippocampal neurogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Neurogenesis and depression: what animal models tell us about the link

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Molecular genetics of bipolar disorder and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Gene expression and association analyses of LIM (PDLIM5) in bipolar disorder and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Divalproex in the treatment of bipolar depression: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

GSK-3: tricks of the trade for a multi-tasking kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Epigenetic programming by maternal behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

An open-label trial of riluzole in patients with treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Mood stabilizer psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

The Wnt signaling pathway in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

The cellular neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.1.93

21 January 2018

Identifiers

DOI

10.1586/14737175.8.1.93

1 reference

17 August 2017

1 reference